Cabozantinib Combinations Generate Excitement in RCC
Published: Wednesday, Apr 08, 2020
Rana R. McKay, MD
Since the FDA approval of cabozantinib (Cabometyx) for use patients with in renal cell carcinoma (RCC), research efforts have been examining the agent in combination with immunotherapy and dual immunotherapy to further improve patient outcomes, according to Rana R. McKay, MD.
... to read the full story